Insider · CIK 0001827317
Nur Nicholson
officer
Files at APLS (Apellis Pharmaceuticals, Inc.), KLRA (Kailera Therapeutics, Inc.). First filing Jan 14, 2025, latest Jan 23, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 7
$0 bought, $554k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Apellis Pharmaceuticals, Inc. | $168k 7,725 shares | -10% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $44k 2,203 shares | -3% | - | |
| 37Weak | Apellis Pharmaceuticals, Inc. | $58k 2,618 shares | -3% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $24k 825 shares | -1% | - | |
| 40Moderate | Apellis Pharmaceuticals, Inc. | $120k 3,948 shares | -4% | - | |
| 38Weak | Apellis Pharmaceuticals, Inc. | $64k 2,145 shares | -4% | - | |
| 38Weak | Apellis Pharmaceuticals, Inc. | $76k 2,632 shares | -5% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 7, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +220,000 | $0.00 | $0 | 220,000 | 33 d ago |
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +45,220 | $0.00 | $0 | 116,338 | Jan 30, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -7,725 | $21.77 | $168k | 71,118 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,203 | $19.79 | $44k | 78,843 | Jan 21, 2026 |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,618 | $22.19 | $58k | 81,046 | Jan 15, 2026 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -825 | $29.52 | $24k | 83,664 | Jan 30, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,948 | $30.43 | $120k | 84,489 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,145 | $29.96 | $64k | 52,011 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +36,426 | $0.00 | $0 | 88,437 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,632 | $28.70 | $76k | 54,156 | Jan 14, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.